Dhanashree S. Kelkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dhanashree S. Kelkar has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Abigail Read
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
1 shared publication- Akhilesh Pandey
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication Alex J. Cole
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, and
1 shared publication- Alexander Joseph Ambinder
Department of Oncology Johns Hopkins University Baltimore Maryland USA
1 shared publication Amy E. DeZern
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, and
1 shared publication- Anil Kumar Madugundu
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
1 shared publication
Latest Publications
- 30 September 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 129 (11) , 4708-4723
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.
- 30 September 2019
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 129 (11) , 4708-4723
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.